A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Boehringer Ingelheim
Nouscom SRL
Werewolf Therapeutics, Inc.
Hoffmann-La Roche
University of California, San Diego
M.D. Anderson Cancer Center
Centre Leon Berard
Novartis
National Institutes of Health Clinical Center (CC)
Inhibrx Biosciences, Inc
Amgen
Astellas Pharma Inc
Vividion Therapeutics, Inc.
Mirati Therapeutics Inc.
BioAtla, Inc.
DEKA Biosciences
Merck Sharp & Dohme LLC
Duke University
Carisma Therapeutics Inc
University of California, San Diego
Lyvgen Biopharma Holdings Limited
Salubris Biotherapeutics Inc
ENB Therapeutics, Inc
MedImmune LLC
Mural Oncology, Inc
R-Pharm
R-Pharm